Comparison of virological responses of children commenced on an abacavir versus stavudine based antiretroviral regimen at King Edward VIII Hospital : Durban. by Montgomery, Stephane.
i 
 
COMPARISON OF VIROLOGICAL RESPONSES OF CHILDREN 
COMMENCED ON AN ABACAVIR VERSUS STAVUDINE BASED 





Stephane Montgomery( MBChB,FCPAED SA) 
 
Submitted in partial fulfilment of the academic requirements for the degree 
MMed 
in the Department of Paediatrics 
School of Clinical Medicine 
College of Health Sciences 




As the candidate's supervisor I have approved this thesis for submission 
 
Signed:_______________    Name: Dr M Archary            Date:  July 2016 
 
 






I Stephane Montgomery declare that: 
(i) The research reported in this dissertation, except where otherwise indicated, is my original work. 
(ii) This dissertation has not been submitted for any degree or examination at any other University. 
(iii) This dissertation does not contain other persons' data, pictures, graphs or other information, 
unless specifically acknowledged as being sourced from other persons. 
(iv) This dissertation does not contain other persons' writing, unless specifically acknowledged as 
being sourced from other researchers. Where other written sources have been quoted then: 
a) their words have been re-written but the general information attributed to them has been referenced; 
b) where their exact words have been used, their writing has been placed inside quotation marks, and 
referenced. 
(v)Where I have reproduced a publication of which I am an author, co-author or editor, I have 
indicated in detail which part of the publication was actually written by myself alone and have fully 
referenced such publications. 
(vi) This dissertation does not contain text, graphics or tables copied and pasted from the internet, 
unless specifically acknowledged, and the source being detailed in the dissertation and in the 
References sections. 
 









I am extremely grateful to my supervisor, Dr M Archary for his expert guidance and support he 
provided to me over last 4 years. 
I would also like to thank Fikile Nkwanyana for her assistance with statistical analysis. 
























Overview of thesis 
The Joint United Nations Programme on HIV/AIDS (UNAIDS) estimated that in 2014 just over 160 
000 children in South Africa were receiving highly active antiretroviral treatment(HAART), 
accounting for 20% of the global HAART cohort. Finding the appropriate HAART regimen that is 
safe, well tolerated and efficacious is of extreme importance in ensuring continued and ongoing 
success of the Paediatric HAART program. In 2010 the World Health Organisation(WHO), due to 
concerns of short and long term stavudine(d4T) toxicity changed the recommendation regarding first-
line HAART regimen from a stavudine based regimen . In South Africa, an Abacavir (ABC) based 
regimen was chosen as the preferred background regimen. However questions have been raised as to 
whether this change has replaced the safety concerns associated with stavudine with a less efficacious 
regimen. A retrospective chart review was conducted to evaluate the virological responses at 6 and 12 
months post HAART initiation in an abacavir cohort at King Edward VIII hospital between January 
2012 – December 2012. Data of 94 children under the age of 12 years who were initiated on an 
abacavir and lamivudine with either lopinavir/ritonavir or efavirenz regimen (abacavir cohort) were 
analysed using Fisher’s exact test and logistical regression to evaluate virological suppression at 12 
months. The data was compared to a prior retrospective chart review conducted between 2004 – 2010 
at King Edward VIII Hospital during which stavudine and lamivudine with either lopinavir/ritonavir 
or efavirenz regimen (stavudine cohort) was the standard of care. The primary objectives were to 
describe the demographic characteristics (age, sex, WHO stage), baseline characteristics (CD4+ count, 
viral load, diagnosis of tuberculosis (TB), HAART regimen) and the virological responses at six 
months and 12 months in children in the abacavir cohort and to compare these to children in the 
stavudine cohort. It is hoped that this information can be used as an adjunct to other studies that have 
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Background: UNAIDS estimated that in 2014 just over 160 000 children in South Africa were 
receiving HAART, accounting for 20% of the global HAART cohort. Finding the appropriate 
HAART regimen that is safe, well tolerated and efficacious is of extreme importance in ensuring 
continued and ongoing success of the Paediatric HAART program.  
In 2010 the World Health Organisation, due to concerns of short and long term stavudine toxicity 
changed the recommendation regarding first-line HAART regimen from a stavudine based regimen. 
In South Africa, an abacavir based regimen was chosen as the preferred background regimen. 
However questions have been raised as to whether this change has replaced the safety concerns 
associated with stavudine with a less efficacious regimen.  
 
Method: A Retrospective chart review was conducted to evaluate the virological responses at 6 and 
12 months in a cohort of children initiated on an abacavir based regimen at King Edward VIII hospital 
between January 2012 – December 2012. Data of 94 children under the age of 12 years who were 
initiated on abacavir and lamivudine with either lopinavir/ritonavir or efavirenz regimen (abacavir 
cohort) were analysed using Fisher’s exact test and logistical regression to evaluate virological 
suppression at 12 months. The data was compared to a prior retrospective chart review conducted 
between 2004 – 2010 at King Edward VIII Hospital during which a stavudine and lamivudine with 
either Lopinavir/ritonavir or efavirenz (stavudine cohort) was the standard of care. 
 
Results: In both the abacavir cohort and stavudine cohort there was no difference in gender 
distribution and the mean age of initiation was 6years. In the abacavir cohort, 62,8% were initiated on 
ABC/3TC/EFV and 37,2% on ABC/3TC/KAL. 88,4% were initiated on D4T/3TC/EFV and 11,6% 
were initiated on D4T/3TC/KAL in the stavudine cohort.  
The virological suppression rate in the abacavir cohort was 80.7% compared to 85.2% in the 
stavudine cohort, which was not a significant difference (p= 0,38:). In the abacavir cohort there was 
no statistical significant difference in virological suppression between patients on efavirenz versus 




Conclusion: This study demonstrates that children treated with an abacavir based regimen have a 
good probability of virological suppression, and there was no statistical difference between patients 
initiating an abacavir-based regimen versus a stavudine based regimen. These findings are in keeping 
with data from several clinical trials and support the WHO recommendation of an abacavir-based 





Part 1 Literature Review 
Objective 
The objective of this literature review was to assess virological responses in children on different 
HAART regimens  in order to determine which HAART regimen is the most safe and effective 
regimen to use in children. 
A literature review was performed to address the following specific questions: 
1. Is HAART effective in children in reaching virological suppression? 
2. Which NRTI regimen will be the most efficacious for the HAART regimen in children? 
3. Which NNRTI will be the most efficacious for the HAART regimen in children? 
 
Search Strategy 
A broad search was conducted on a number of database platforms: 
 Pubmed 
 The Cochrane database 
 
Search terms used included MeSh terms and free text: 
 HIV, Child, paediatric, Virological responses, abacavir, stavudine, NRTI regimen, Efavirenz 
based regimen, Protease inhibitor regimens. 
 
The bibliographies of relevant articles were also searched for additional papers. The search was 
initially done in October 2013 and repeated again in June 2016 prior to this submission. 
 
Acceptable studies/inclusion criteria 
Population: Adults and children 
Intervention: Antiretroviral regimens 
Comparator: Different HAART regimens 
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Outcome: Treatment outcome- Virological response 
Results of search: 
There were several clinical trials that have been conducted to determine optimal ART regimens with 
careful attention being given to evaluating the efficacy of protease inhibitors (PI) versus non-
nucleoside reverse transcriptase inhibitors (NNRTI) for paediatric first line regimens. Relatively little 
attention has been given to the nucleoside reverse transcriptase inhibitor(NRTI) “backbone” of the 
regimens. 
There were 2 RCT studies, 3 cohort studies and one systematic review that compared an ABC based 
regimen to other NRTI regimens from paediatric data. There were one multicentre open labelled 
clinical trial and one meta-regression analysis found comparing ABC based regimen to other NRTI's 
from Adult data.  
There were 3 clinical trials, one secondary analysis and one retrospective cohort study in the 
paediatric group comparing protease inhibitors vs. NNRTI's. 

















Improvement in the prevention of mother to child transmission (PMTCT) program and availability of 
treatment of human immunodeficiency virus(HIV) infected children has reduced the number of 
children acquiring HIV infection. In 2013, 200 000 (170 000–230 000) children were newly infected 
with HIV. This is 43% lower than in 2009. Twenty four per cent of children living with HIV received 
HAART, based on 2014 Joint United Nations Program for HIV/AIDS (UNAIDS) report.1   In South 
Africa 158,539 children are on highly active antiretroviral treatment(HAART), of which 33,5% 
(53110) live in KZN.2 In the absence of treatment, Newell et al suggested that without optimal 
therapy, 52,5% of HIV-infected children living in Africa died by 24 months of age.3 
 
The South African National HAART program started in 2004, and the recommended first line 
paediatric antiretroviral regimen was stavudine, lamivudine with either lopinavir/ritonavir(LPV/r) for 
children under the age of three, or efavirenz for children over the age of three. In 2010, the South 
African National HAART guidelines replaced stavudine with abacavir (ABC) in the first line regimen 
due to concerns of stavudine toxicity, following World Health Organization (WHO) 
recommendations. The eligibility criteria also changed from based on the patients WHO clinical stage 
or CD4 count to a treat all strategy for children under five years of age in 2013.4 
The ultimate aim of HAART is to reach virological suppression, which is defined as a viral load 
below 50copies/ml. Virological suppression is dependent on a variety of factors such as adherence 
and acquisition of mutations resulting in drug resistance.5 
Stavudine has a comparatively higher genetic barrier to resistance than ABC, therefore theoretically a 
stavudine based regimen should be able to tolerate sub optimal compliance better than an ABC based 
regimen.6  Exposure to sub-optimal HAART drug levels results in the virus acquiring mutations 
conferring resistance to the drug. The common drug resistance mutations to ABC are M184V/I, 
K65R,L74V. The combination of M184V/I and L74V reduces abacavir susceptibility more than 
fivefold, whereas the M184V mutation actually reduces the resistance to stavudine.6  In comparison, 
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common drug resistance mutations to stavudine are thymidine analogue mutations (TAM) 
namelyM41L, L210W,D67N,K70R  T215Yand K219Q/E. TAMs are involved in resistance to all 
nucleoside reverse transcriptase inhibitors(NRTIs), except lamivudine (3TC), but the degree of cross-
resistance depends on the NRTI considered and the number of TAMs on the virus. 
 
As mentioned earlier, adherence to HAART is essential to prevent drug resistance. Therefore the 
formulations of the different antiretroviral drugs are an important factor to ensure compliance. ABC is 
available as a paediatric syrup and tablet and can be stored at room temperature. However stavudine 
oral solution requires refrigeration after reconstitution. The storage of these drugs is an especially 
important factor to consider in the setting where most households access to electricity and 
refrigeration are limited.7 
 
Coupled with the ease of administering and storage of treatment, the side effect profile is also of 
particular concern when considering the ideal regimen for children. Adverse events associated with 
stavudine include mitochondrial toxicity, peripheral neuropathy, lipoatrophy, pancreatitis, lactic 
acidosis/severe hepatomegaly, hyperlipidaemia and insulin resistance.Lipodystrophy syndrome refers 
to peripheral lipo-atrophy, central lipohypertrophy and dyslipidaemia associated with insulin 
resistance resulting in permanent disfigurement. 
In a recent review article, Innes et al described that lipodystrophy syndrome in HIV infected children 
on HAART was common in patients on didanosine, stavudine or zidovudine. The authors concluded 
that paediatric dosing of stavudine need to be reduced urgently to minimize the risk of lipodystrophy.8  
Abacavir is a NRTI with fewer side effects than stavudine. Its only potential dangerous side effect is a 
hypersensitivity reaction that is more common in the Caucasian population than African population 
due to the infrequency of the HLA B5701 haplotype in the African population.  A study by Walter 
Hughes et al concluded that abacavir is safe and well tolerated in children and the single ABC related 
adverse event was the hypersensitivity reaction.9 
 




Comparing ABC regimen to other NRTI  regimens: Paediatric data 
There were 2 randomized controlled trials , 3 cohort studies and one systematic review that compared 
an ABC based regimen to other NRTI regimens. 
The Paediatric European Network for the Treatment of AIDS study ( PENTA-5) trial published in the 
AIDS journal, 2007, main objective was to describe the long-term efficacy over 5 years of regimens 
including combinations of abacavir, lamivudine and/or zidovudine in previously untreated children. It 
was a 48-week randomised controlled trial that compared three dual nucleoside reverse transcriptase 
inhibitor (NRTI) combinations as part of HAART. 128 HAART-naïve children were randomised to 
zidovudine\lamivudine (n = 36), zidovudine\abacavir (45) or lamivudine\abacavir (47). 
Asymptomatic children (n = 55) were also randomised to nelfinavir or placebo; all 
other children received open-label nelfinavir. The median follow-up was 5.8 years. By 5 years, 17 
(47%), 28 (64%) and 18 (39%) children had changed their randomised NRTIs in the 
zidovudine\lamivudine, zidovudine\abacavir and lamivudine\abacavir groups respectively, but 18%, 
50% and 50% of these changes were either early single drug substitutions for toxicity or switches 
with viral suppression (HIV-1 RNA < 400 copies/ml; e.g. to simplify regimen delivery). At 5 years, 
55%/32% zidovudine\lamivudine, 50%/25% zidovudine\abacavir and 79%/63% lamivudine\abacavir 
had HIV-1 RNA < 400/< 50 copies/ml respectively (p = 0.03/p = 0.003). The five year data 
demonstrated that lamivudine\abacavir is more effective in terms of HIV-1 RNA suppression and 
growth changes, with lower rates of switching with detectable HIV-1 RNA than 
zidovudine\lamivudine or zidovudine\abacavir, and they recommended that lamivudine/abacavir 
should be preferred as first-line NRTI backbone.10 
 
Similarly, Musiime et al conducted an open labelled parallel-group, randomised controlled trial 
between Nov 8, 2010, and Dec 28, 2011,where they enrolled  HIV- infected children from Uganda 
and Zambia. This was the first randomised controlled trial in African children, conducting a head-to-
head comparison of the three most relevant NRTIs for paediatric treatment.480 Children were 
randomised: 156 to stavudine, 159 to zidovudine, and 165 to abacavir. After two were excluded due to 
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randomisation error, 156 children were analysed in the stavudine group, 158 in the zidovudine group, 
and 164 in the abacavir group, and followed for median 2·3 years (5% lost to follow-up). 365 (76%) 
were HAART naive .917 grade 2–4 clinical or grade 3/4.At 48 weeks, 98 (85%), 81 (80%) and 95 
(81%) HAART-naive children in the stavudine, zidovudine, and abacavir groups, respectively, had 
viral load less than 400 copies per ml (p=0·58); most HAART-experienced children maintained 
suppression (p=1·00). Most HAART-naive children achieved viral load less than 400 copies per mL 
by 48 weeks, with no differences between randomised groups (p=0·58). Viral load less than 400 
copies per ml was maintained at 48 weeks by more than 96% HAART-experienced children 
(p=1·0).11 This study concluded that none of the NRTI's were superior and all the NRTI's were 
capable of producing virological suppression in children. 
 
There were 3 local South African cohort studies conducted to evaluate virological responses in 
children on abacavir vs. stavudine based HAART regimen. A cohort analysis by Brennan et al had 
similar findings to Musiime et al. The study participants were initiated in one of 8 HIV clinics in 
Gauteng and Mpumalanga, South Africa.317 (56.9%) patients initiated stavudine and 240 (43.1%) 
abacavir. They defined virologic failure as the proportion of participants with a viral load of more 
than 400 copies/ml after 24 months of treatment. They detected no difference in virologic failure 
between abacavir regimen and stavudine regimen (RR 1.01; 95 % CI 0.73–1.39; n = 
557).However the quality of the evidence for this outcome was considered low.12 
 
The other two South African cohort studies showed contrasting evidence to the above clinical trials 
and cohort study. 
Technau and Lazarus et al conducted a retrospective analysis of the virological outcomes among 
children receiving different starting regimens at Empilweni clinic at Rahima Moosa Mother and Child 
Hospital (RMMCH), a large paediatric HIV treatment centre in Johannesburg, South Africa. Among 
2423 children who initiated HAART at RMMCH from April 2004 until 28 December2011, 2036 
(84%) were included and had initiated d4T/3TC+LPV/r (n=672); ABC/3TC+LPV/r (n=192); 
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d4T/3TC+EFV (n=962) or ABC/3TC+EFV (n=210). The children excluded had initiated other 
regimens (n=387, including nevirapine, ritonavir, didanosine,zidovudine and ‘super-boosted’ LPV/r 
for concurrent rifampicin usage).At both 6 and 12 months, fewer children reached virological 
suppression and median VL logs were higher in children receiving ABC compared to d4T, in both the 
EFV and LPV/r treated children. In children treated with LPV/r-based regimens, 71% receivingd4T 
versus 40% receiving ABC had VL<400 copies/ml at 6 months (p<0.0001). Similarly, in those on 
EFV, 91% versus 67% had VL<400 copies/ml at 6 months when receiving d4TversusABC 
(p<0.0001). Time to viral suppression was significantly longer and time to viral rebound (>1000 
copies/ml) after suppression shorter in the ABC-treated children for both LPV/r and EFV-based 
regimens. A stronger association was seen in the LPV/r-based regimens, where children on ABC had 
an almost 2-fold increased risk of failure to suppress (41% versus21%, log-rank p<0.0001) by 12 
months. Children receiving EFV had an almost 2-fold higher risk of rebound by 12 months after first 
suppression (35% versus 18%, log-rank p=0.0001) if they were on ABC compared to d4T.These data 
demonstrate that children treated with ABC/3TC had a lower probability of viral 
suppression at 6 and 12 months and a higher probability of virological rebound than those treated with 
d4T/3TC in both LPV/r- and EFV-based regimens, even after adjustment for calendar time and other 
potential confounders.13 
 
Similarly, a South African Multi-Cohort Analysis was then conducted by Technau and Schomaker et 
al evaluating the virological response in children treated with abacavir compared with stavudine-
based antiretroviral treatment. Data for 9543 HAART-naïve children <16 years at treatment initiation 
started on either stavudine/lamivudine (d4T/3TC) or ABC/3TC with efavirenz (EFV) or ritonavir-
boosted lopinavir(LPV/r) treated at six clinics in Johannesburg and Cape Town, South Africa, were 
analysed with Chi-square tests and logistic regression to evaluate viral suppression at six and twelve 
months. Prevalence of viral suppression at six months in 2174 children started on a d4T-based LPV/r 
regimen was greater (70%) than among 438 children started on an ABC-based LPV/r regimen (54%, 
p<0.0001). Among 3189 children started on a d4T-based EFV regimen a higher proportion (86%) 
achieved suppression at six months compared to 391 children started on ABC containing 
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EFV regimens (78%, p<0.0001). Relative benefit of d4T vs. ABC on six month suppression remained 
in multivariate analysis after adjustment for pre-treatment characteristics, cohort and year of program 
(LPV/r – OR 0.57 [CI: 0.46–0.72]; EFV – OR 0.46 [CI: 0.32–0.65]).They concluded that this 
expanded analysis is consistent with their previous report of worse virological outcomes after ABC 
was introduced as part of first-line ART in South Africa.14 
 
Adetokunboh et al conducted a systematic review and meta-analysis to determine the efficacy and 
safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected 
children and adolescents. They included two randomised controlled trials (RCTs) and two analytical 
cohort studies with a total of 10,595 participants. Among the RCTs they detected no difference in 
virologic suppression after a mean duration of 48 weeks between abacavir- and stavudine-containing 
regimens (2 trials; n = 326: RR 1.28; 95 % CI 0.67–2.42) with significant heterogeneity (P = 0.02; I2 
= 81 %). They also found no significant differences between the two groups for adverse events and 
death. After five years of follow-up, virologic suppression improved with abacavir (1 trial; n = 69: RR 
1.96; 95 % CI 1.11–3.44). For cohort studies, they detected that the virologic suppression activity of 
abacavir was less effective than stavudine in both the lopinavir/ritonavir (1 study, n = 2165: RR 0.79, 
95 % CI 0.67–0.92) and efavirenz sub-groups (1 study, n = 3204: RR 0.79, 95 % CI 0.67–0.92) 
respectively. The quality of evidence from RCTs was moderate for virologic suppression but low for 
death and adverse events, while that of cohort studies was low for all three these outcomes. They 
concluded that available evidence showed little or no difference between abacavir-containing regimen 
and other NRTIs regarding efficacy and safety when given to children and adolescents as a first-line 
antiretroviral therapy.15 
 
In order to extrapolate from the above results one has to take into account the nature of the studies. 
The two randomised controlled trials were done in an ideal study setting where patients are closely 
monitored and followed up, ensuring better compliance to treatment. Whereas the cohort studies are 
more reflective of the real world environment where compliance maybe suboptimal and drug stock-
outs may result in interruptions in antiretroviral treatment. The low genetic barrier of ABC for the 
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development of drug resistance may therefore predispose patients on an ABC containing regimen with 
sub-optimal compliance to treatment failure. 
 
Comparing ABC regimen to other NRTI  regimens: Adult data 
As with the paediatric data, there are also conflicting results in the literature with regards to 
virological performance of an abacavir based regimen. 
 
DeJesus et al conducted a multicenter, randomized, double-blind non-inferiority clinical trial that 
compared the efficacy and safety of abacavir with that of zidovudine plus lamivudine and efavirenz in 
649 HAART-naive HIV-infected patients. Their primary objective was a comparison of proportions 
of patients achieving plasma HIV-1 RNA levels<50 copies/ml through week 48 of the study. Their 
results concluded that  70% of patients in the abacavir group, compared with 69% in the zidovudine 
group, maintained confirmed plasma HIV-1 RNA levels of <50 copies/ml (in the intent-to-treat 
exposed population).Virologic failure was infrequent (6% in the abacavir group and 4% in the 
zidovudine group). There was a significant CD4+ cell response (209 cells/mm3 in the abacavir group 
and 155 cells/mm3 in the zidovudine group).Safety profiles were as expected. They concluded that 
abacavir provided an effective and durable antiretroviral response that was non-inferior to zidovudine, 
when combined with lamivudine and efavirenz.16 
 
A meta-regression analysis of 12 clinical trials in 5168 patients was conducted by Hill et al. Their 
main objective was to determine the efficacy of Tenofovir/emtricitabine (TDF/FTC) vs. 
abacavir/lamivudine (ABC/3TC) with ritonavir (RTV)-boosted protease inhibitors (PIs).From the 
12 clinical trials of 5168 HAART-naïve patients, 3399 patients on TDF/FTC and 1769 patients 
ABC/3TC was used with RTV-boosted PI. Across all the trials, HIV RNA suppression rates were 
significantly higher for those with baseline viral load below 100,000 copies/ml (77.2%) vs. above 
100,000 copies/ml (70.9%) (P=0.0005). For the trials of lopinavir/ritonavir (LPV/r), 
atazanavir/ritonavir (ATV/r) and fosamprenavir/ritonavir (FAPV/r) using either TDF/FTC or 
ABC/3TC, the HIV RNA responses were significantly lower when ABC/3TC was used, relative to 
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TDF/FTC, for all patients (P=0.0015) and for patients with baseline viral load <100,000 copies/ml 
(70.1%vs. 80.6%, P=0.0161), and was borderline for those with viral load >100,000 copies/ml 
(67.5%vs. 71.5%, P=0.0523). They concluded that  their analysis suggests higher efficacy for first-
line use of a TDF/FTC NRTI backbone with boosted PIs, relative to use of ABC/3TC.17 
It is difficult to apply adult studies to the paediatric population due to differences in pharmocokinetics 
and pharmacodynamics, however the meta-regression analysis findings is of concern regarding the 
efficacy of ABC and high VLs especially as paediatric patients often have higher VL at initiation than 
adult patients.. 
Comparing Protease inhibitors to NNRTI regimens: Paediatric data 
Results from the previously 2 mentioned South African cohort studies on the comparison of abacavir 
vs. stavudine, actually found that patients on PI treatment had worse virological performances than 
patients on EFV. 
The PENPACT- 1 trial was the first open label long term randomised trial to compare  protease 
inhibitor(PI) and non-nucleoside reverse transcriptase inhibitor(NNRTI) first line HAART in HIV-
infected children. The PENPACT-1 trial assessed the long-term effectiveness of HAART-naïve 
children from Europe and North/South America initiating 2NRTIs+PI vs. 2NRTIs+NNRTIin a 
randomised open-label factorial design. The primary outcome was VL change between baseline and 4 
years. A total of 266 children (133 Europe, 77 North America, 56 South America) from 68 centres in 
13 countries were randomised between September 2002 and September 2005. 
266 children were randomised and 263 analysed. The median age was 6.5years; mean(SD), CD4 
18%(11); VL 5.1(0.8)log10c/ml. Median follow-up was 5.0years; 188(71%) children were on first-
line HAART at trial end. At 4 years, mean VL reductions were −3.16 vs. −3.31log10c/ml for PI vs. 
NNRTI(difference p=0.26).VL was <400c/ml in 82%PI vs82%NNRTI, p=0.91.There was no 
difference between initiating HAART with PI or NNRTI-based regimens; both achieved good long-




Similar findings were found in the PROMOTE trial where they analysed virologic and immunologic 
outcomes of HIV-infected Ugandan children randomized to lopinavir-ritonavir or non-nucleoside 
reverse-transcriptase-inhibitor therapy. Of 185 children enrolled, 91 initiated LPV/r and 92 initiated 
NNRTI-based HAART. At baseline, the median age was 3.1 years (range: 0.4 to 5.9) and 131 (71%) 
were HAART-naive. The proportion of children with virologic suppression at 48 weeks was 80% 
(67/84) in the LPV/r-arm vs. 76% (59/78) in the NNRTI-arm, a difference of 4% (95%CI: −9% to 
+17%). Time to virologic failure, CD4+changes, were similar between arms. They concluded that 
LPV/r-based HAART was not associated with worse virologic efficacy, immunologic efficacy, or 
adverse event rates compared to NNRTI-based HAART.19 
 
Local South African studies also confirmed that patients initiating a PI regimen showed satisfactory 
virological suppression rates. Teasdale et al conducted a secondary analysis of data collected during 
the pre-randomization phase of an HAART strategies trial conducted at a single site in Johannesburg, 
South Africa. The main objective of the study was to investigate if there is the association between 
adherence and viral suppression among infants and young children initiated on PI Therapy. By 24 
weeks, 197/269 (73%) children achieved viral suppression. This study showed high proportions of 
viral suppression and medication adherence in this cohort of infants and young children initiating 
protease inhibitor based antiretroviral treatment in South Africa.20 
 
Similarly Jaspan et al conducted retrospective cohort study to evaluate the clinical and laboratory 
outcomes of 391 children who received protease inhibitor (PI) or non-nucleoside reverse transcription 
inhibitor (nNRTI)-containing highly active antiretroviral regimens (HAART) from a Cape Town 
clinic. This cohort achieved a sustained doubling of median CD4+% from baseline, steady increase of 
median WAZ, and survival of 91%, despite only 49% virologic suppression at 24 months. However, 
when analysed according to regimen, PI-containing regimens had better virologic suppression at all 





The PROMOTE and PENPACT-1 trial showed no difference in virological outcomes in initiating 
with a ritonavir-boosted lopinavir (LPV/r)- vs. nevirapine-based therapy in prophylaxis-exposed 
children. 
In contrast to these above mentioned studies the P1060 study which provided  evidence of the 
superiority of ritonavir-boosted lopinavir–based regimens over nevirapine-based regimens in terms of 
both efficacy and safety.The P1060 trial was two parallel, randomized clinical trials comparing 
nevirapine with ritonavir-boosted lopinavir in nevirapine-exposed vs. nevirapine-unexposed, in 
addition to zidovudine and lamivudine, in HIV-infected, ART-eligible children between 2 and 36 
months of age. The randomized trial was conducted in six African countries and India, The primary 
end point of both cohorts was virologic failure or discontinuation of treatment by study week 24. 
The results of cohort 1(nevirapine exposed) showed a total of 164 children were enrolled. The median 
percentage of CD4+ lymphocytes was 19%; a total of 56% of the children had WHO stage 3 or 4 
disease. More children in the nevirapine group than in the ritonavir-boosted lopinavir group reached a 
primary end point (39.6% vs. 21.7%; weighted difference, 18.6 percentage-points; 95% confidence 
interval, 3.7 to 33.6; nominal P=0.02). Baseline resistance to nevirapine was detected in 18 of 148 
children (12%) and was predictive of treatment failure.  
 The results of cohort 2 showed a total of 288 children were enrolled; the median percentage of CD4+ 
T cells was 15%, and the median plasma HIV type 1 (HIV-1) RNA level was 5.7 log10 copies per 
milliliter. The percentage of children who reached the primary end point was significantly higher in 
the nevirapine group than in the ritonavir-boosted lopinavir group (40.8% vs. 19.3%; P<0.001). 
Among the nevirapine-treated children with virologic failure for whom data on resistance were 
available, more than half (19 of 32) had resistance at the time of virologic failure. In addition, the time 
to a protocol-defined toxicity end point was shorter in the nevirapine group (P=0.04), as was the time 
to death (P=0.06).The conclusion of both cohorts was that  outcomes were superior with ritonavir-
boosted lopinavir among young children.  These data support ritonavir-boosted lopinavir as the basis 
for first-line ART in all children younger than 3 years of age, regardless of whether they have had 
prior NNRTI exposure. 
Factors that may have contributed to the suboptimal results with nevirapine include elevated viral load 
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at baseline, selection for nevirapine resistance, background regimen of nucleoside reverse-
transcriptase inhibitors, and the standard ramp-up dosing strategy.  Since nevirapine is used for both 
treatment and perinatal prevention of HIV infection in resource-limited settings, alternative strategies 
for the prevention of HIV transmission from mother to child, as well as for the treatment of HIV 
infection, are urgently required.22,23  
 
 
Virological outcomes of children on HAART: International studies 
Several studies were also included to evaluate virological responses in children on HAART. These 
studies confirm that children had favourable virological responses to HAART. 
 
A multi centre national cohort was conducted to assess the long term virological outcome in children 
on antiretroviral treatment in the UK and Ireland. Nine hundred and ninety-seven children started 
HAART at a median age of 7.7 years (inter-quartile range 2.9–11.7), 251 (25%) below 3 years: 411 
(41%) with efavirenz and two nucleoside reverse transcriptase inhibitors (EFV+2NRTIs), 264(26%) 
with nevirapine and two NRTIs (NVP+2NRTIs), 119 (12%; 106 NVP, 13EFV) with non-nucleoside 
reverse transcriptase inhibitor and three NRTIs(NNRTI+3NRTIs), and 203 (20%) with boosted 
protease inhibitor-based regimens. Median follow-up after HAART initiation was 5.7 (3.0–8.8) years. 
Viral load was less than 
400 copies/ml by 12 months in 92% [95% confidence interval (CI) 91–94%] of the children. Time to 
suppression was similar across regimens (P¼0.10), but faster over calendar time, with older age and 
lower baseline viral load. Their results showed that viral load suppression by 12 months was high with 
all regimens.NVP+3NRTIs regimens were particularly efficacious in the longer term and may be a 
good alternative to protease inhibitor-based ART in young children.24 
 
Another study done in India , also assessed the immunological, virological and clinical responses to 
HAART in children. 175 children (boys: 74.9%) were included in the study, with a median follow up 
of 43 (IQR:17, 68) months. The median age at diagnosis was 119 (IQR: 75, 156) months. The median 
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CD4+ count at start of HAART was 340 cells/μL (IQR: 185,704), which increased to 924 cells/μL 
(IQR:591,1278) at 48 months after HAART and plateaued at 749 (IQR: 542,1056) cells/ μL after 90 
months of therapy. Viral load was available in 76 children. After a median duration of 34.4 months 
(IQR: 10.4, 47) of HAART the median viral load documented was 400 (IQR:47, 958)RNA 
copies/mL; 49 (66%) children had undetectable viral load. 
The weight for age (WAZ) and height for age (HAZ) z score both showed improvement with time 
after HAART initiation [baseline: WAZ −2.8 (IQR:-4,-1.6), HAZ −2.1 (IQR:-3.4,-0.69); at 42 months 
of therapy: WAZ −1.2 (IQR:-2.1, 0.01), HAZ −0.75(IQR:-1.6,-0.37)]. Adverse events were reported 
in 21 (12%)children. Non-adherence to therapy, treatment failure and death were noted in 35 (20%), 9 
(5.1%) and 6 (3.4%) children respectively. This study did not specify the HAART regimens that the 
children were receiving. They concluded that HAART in HIV-infected children is effective, safe and 
is associated with good immunological and virological response as well as improvement in growth 
parameters.25 
 
Similarly a study done in Central China concluded that HAART is an effective strategy for inhibiting 
HIV replication and reconstructing the immunological response in children with AIDS. Twenty-six 
HIV-1-infected children receiving HAART in Hubei province, China, were enrolled retrospectively in 
this study. The median duration of HAART was 41 months (18–72.3 months). In children showing 
clinical improvement, high viral suppression rate below log10 (2.7) copies/ml by the third months of 
HAART was observed. The median CD4+cell counts reached to 820.5/μl by 12 months and the median 
ratio of CD4/CD8 increased to 0.6 by 21 months. They concluded that HAART is an effective 
strategy for inhibiting HIV replication and reconstructing the immunological response in children 
with AIDS.26 
 
A local study by Meyer et al also provided reassuring data as their findings demonstrated excellent 
virologic suppression rates and immunologic and somatic growth responses in children receiving 
HAART. Their results showed the cumulative probability of achieving a viral load < 400 copies/ml 
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was 59.4% (95% CI: 57.0%, 61.8%) 6 months after HAART initiation, 84.0% (95% CI: 82.6%, 
86.2%) by 12 months, 96.2% (95% CI: 94.4%,96.7%) by 24 months. Children greater than 3 years at 
HAART initiation (correlating with those who started EFV-based regimens) were more likely to 
achieve virologic suppression early compared with children younger than 3 years (on LPV/r-





Abacavir seems to be an ideal NRTI considering its formulation and low side effect profile. However 
there are conflicting results from the literature regarding the efficacy of an abacavir based regimen in 
producing virological suppression. 
 
There is currently no data available regarding the virological performance in children on an ABC 
based regimen in KwaZulu Natal. 
The purpose of this retrospective chart review was to compare the virological responses of children 













Table 1: Summary of Literature  
 
























 At 48 weeks, 98 (85%), 81 
(80%) and 95 (81%) 
HAART-naive children in 
the stavudine, zidovudine, 
and abacavir groups, 
respectively, had viral load 
less than 400 copies per mL 
(p=0·58) 
 Most HAART-naive 
children achieved viral load 
less than 400 copies per mL 
by 48 weeks, with no 
differences between 
randomised groups (p=0·58).  
 Viral load less than 400 
copies per mL was 
maintained at 48 weeks by 
more than 96% HAART-
experienced children 
(p=1·0). 
Penta 5 Trial 34 centres in  48-week 128  At 5 years, 55%/32% 
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(2002)10 nine countries randomised 
controlled trial  














HIV-1 RNA < 400/< 50 
copies/ml respectively (p = 
0.03/p = 0.003).  
 The five year data 
demonstrate that 
lamivudine\abacavir is more 



























 Children treated with LPV/r-
based regimens, 71% 
receiving d4T versus 40% 
receiving ABC had VL<400 
copies/ml at 6 months 
(p<0.0001).  
 Similarly, in those on EFV, 
91% versus 67% had 
VL<400 copies/ml at 6 
months when receiving d4T 
versus ABC (p<0.0001).  
 Time to viral suppression 
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was significantly longer and 
time to viral rebound (>1000 
copies/ml) after suppression 
shorter in the ABC-treated 
children for both LPV/r and 
EFV-based regimens 
 These data demonstrate that 
children treated with 
ABC/3TC had a lower 
probability of viral 
suppression at 6 and 12 
months and a higher 
probability of virological 
rebound than those treated 
with d4T/3TC in both 

















 Prevalence of viral 
suppression at six months in 
2174 children started on a 
d4T-based LPV/r regimen 
was greater (70%) than 
among 438 children started 
on an ABC-based LPV/r 
regimen (54%, p<0.0001).  
 Among 3189 children started 
on a d4T-based EFV 
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regimen a higher proportion 
(86%) achieved suppression 
at six months compared to 
391 children started on ABC 
containing EFV regimens 
(78%, p<0.0001). 
 Worse virological outcomes 
after ABC was introduced as 
part of first-line ART in 
South Africa 
     
Brennan et al 
(2014)12 









 They detected no difference 
in virologic failure between 
abacavir regimen and 
stavudine regimen (RR 1.01; 
95 % CI 0.73–1.39; n = 557) 
Adetokunboh 
et al(2015)15 




 Among the RCTs they 
detected no difference in 
virologic suppression after a 
mean duration of 48 weeks 
between abacavir- and 
stavudine-containing 
regimens (2 trials; n = 326: 
RR 1.28; 95 % CI 0.67–
2.42) 
 For cohort studies, they 
detected that the virologic 
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suppression activity of 
abacavir was less effective 
than stavudine in both the 
lopinavir/ritonavir (1 study, 
n = 2165: RR 0.79, 95 % CI 
0.67–0.92) and efavirenz 
sub-groups (1 study, n = 
3204: RR 0.79, 95 % CI 
0.67–0.92) respectively 
 Available evidence showed 
little or no difference 
between abacavir-containing 
regimen and other NRTIs 
 





















649 Adults  70% of patients in the 
abacavir group, compared 
with 69% in the zidovudine 
group, maintained confirmed 
plasma HIV-1 RNA levels of 
<50 copies/mL (in the intent-
to-treat exposed population). 
 Virologic failure was 
infrequent (6% in the 
abacavir group and 4% in the 
zidovudine group). 
 They concluded that 
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abacavir provided an 
effective and durable 
antiretroviral response that 
was non-inferior to 
zidovudine, when combined 
with lamivudine and 
efavirenz 
Hill et al 
(2009)17 
  Meta-regression 
analysis of 
12 clinical trials 
5168 
Adults 




(FAPV/r) using either 
TDF/FTC or ABC/3TC, the 
HIV RNA responses were 
significantly lower when 
ABC/3TC was used, relative 
to TDF/FTC, for all patients 
(P=0.0015) and for patients 
with baseline viral 
load <100,000 copies/mL 
(70.1%vs. 80.6%, 
P=0.0161), and was 
borderline for those 
with viral load >100,000 
copies/mL (67.5%vs. 71.5%, 
P=0.0523).  
 They concluded that  their 
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analysis suggests higher 
efficacy for first-line use of a 
TDF/FTC NRTI backbone 
with boosted PIs, relative to 
use of ABC/3TC 













 At 4 years, mean VL 
reductions were −3.16 vs −
3.31log10c/ml for PI vs 
NNRTI(difference p=0.26) 
 VL was <400c/ml in 82%PI 
vs 82%NNRTI, p=0.91  
 There was no difference 
between initiating HAART 
with PI or NNRTI-based 
regimens; both achieved 









 The proportion of children 
with virologic suppression at 
48 weeks was 80% (67/84) 
in the LPV/r-arm vs. 76% 
(59/78) in the NNRTI-arm, a 
difference of 4% (95%CI: 
−9% to +17%) 
 LPV/r-based HAART was 
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not associated with worse 
virologic efficacy, 
immunologic efficacy, or 
adverse event rates 

















 Cohort 1:The 
medianpercentage of 
CD4+ lymphocytes was 
19%; a total of 56% of 
the children had WHO 
stage 3 or 4 disease. 
More children in the 
nevirapine group than in 
the ritonavir-boosted 
lopinavir group reached 
a primary end point 




interval, 3.7 to 33.6; 
nominal P=0.02). 
Baseline resistance to 
nevirapine was detected 
in 18 of 148 children 
(12%) and was 
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predictive of treatment 
failure.  
  The results of cohort 2 
showed a total of 288 
children were enrolled; 
the median percentage 
of CD4+ T cells was 
15%, and the median 
plasma HIV type 1 
(HIV-1) RNA level was 
5.7 log10 copies per 
milliliter. The 
percentage of children 
who reached the 
primary end point was 
significantly higher in 
the nevirapine group 
than in the ritonavir-
boosted lopinavir group 
(40.8% vs. 19.3%; 
P<0.001).  
 Among the nevirapine-
treated children with 
virologic failure for 
whom data on resistance 
were available, more 
than half (19 of 32) had 
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resistance at the time of 
virologic failure  
 The conclusion of both 
cohorts was that  
outcomes were superior 
with ritonavir-boosted 
lopinavir among young 
children 
 




 Secondary analysis 
of data collected 
during the pre-
randomization 







 By 24 weeks, 197/269 (73%) 
children achieved viral 
suppression.  
 This study showed high 
proportions of viral 
suppression and medication 
adherence in this cohort of 
infants and young children 
initiating protease inhibitor 
based antiretroviral 
treatment in South Africa 









 This cohort achieved a 
sustained doubling of 
median CD4+% from 
baseline, steady increase of 
median WAZ, and survival 
of 91%, despite only 49% 
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virologic suppression at 24 
months. 
 However, when analyzed 
according to regimen, PI-
containing regimens had 
better virologic suppression 
at all time points. 
  Their findings confirmed 
that PI regimens achieved 
greater virologic suppression 
than nNRTIs. 
Long term virological outcomes of children on HAART: International studies 
Paediatric Data 
 








 Viral load was less than400 
copies/ml by 12 months in 
92% [95% confidence 
interval (CI) 91–94%] of the 
children. Time to 
suppression was similar 
across regimens (P¼0.10) 
 Their results showed that 
viral load suppression by 12 
months was high with all 
regimens. 
 NVP+3NRTIs regimens 
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were particularly efficacious 
in the longer term and may 
be a good alternative to 
protease inhibitor-based 













 Viral load was available in 
76 children.  
 The median viral load 
documented was 400 
(IQR:47, 958)RNA 
copies/mL; 49 (66%) 
children had undetectable 
viral load 
 HAART in HIV-infected 
children is effective, safe and 
is associated with good 
immunological and 
virological response as well 
as improvement in growth 
parameters. 





 Retrospective chart 
review 
26 Children  In children showing clinical 
improvement, high viral 
suppression rate below log10 
(2.7) copies/ml by the third 




 They concluded that 
HAART is an effective 
strategy for inhibiting HIV 
replication and 
reconstructing the 
immunological response in 









 Their results showed the 
cumulative probability of 
achieving a viral load < 400 
copies/ml was 59.4% (95% 
CI: 57.0%, 61.8%) 6 months 
after HAART initiation, 
84.0% (95% CI: 82.6%, 
86.2%) by 12 months, 96.2% 
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Background: UNAIDS estimated that in 2014 just over 160 000 children in South Africa were 
receiving HAART. In 2010 the World Health Organisation, replaced stavudine with abacavir in the 
first line regimen due to concerns of stavudine toxicity. However questions have been raised as to 
whether this change has replaced the safety concerns associated with stavudine with a less efficacious 
regimen.  
 
Method: A Retrospective chart review was conducted to evaluate the virological responses at 6 and 
12 months in a cohort of children initiated on an abacavir based regimen at King Edward VIII hospital 
between January and December 2012. Data of 94 children under the age of 12 years who were 
initiated on abacavir and lamivudine with either lopinavir/ritonavir or efavirenz regimen (abacavir 
cohort) were analysed using Fisher’s exact test and logistical regression to evaluate virological 
suppression at 12 months. The data was compared to a prior retrospective chart review conducted 
between 2004 and 2010 at King Edward VIII Hospital during which stavudine and lamivudine with 
either lopinavir/ritonavir or efavirenz (stavudine cohort) was the standard of care. 
 
Results: In both the abacavir cohort and stavudine cohort there was no difference in gender 
distribution and the mean age of initiation was 6 years. In the abacavir cohort, 62, 8% were initiated 
on ABC/3TC/EFV and 37, 2% on ABC/3TC/KAL. 88, 4% were initiated on D4T/3TC/EFV and 11, 
6% were initiated on D4T/3TC/KAL in the stavudine cohort.  
The virological suppression rate in the abacavir cohort was 80.7% compared to 85.2% in the 
stavudine cohort, which was not significant (p= 0, 38). 
 
Conclusion: This study demonstrated that children treated with an abacavir based regimen have a 
good probability of virological suppression. These findings are in keeping with data from several 
clinical trials and support the WHO recommendation of an abacavir-based regimen for infants and 











Improvement in the prevention of mother to child transmission (PMTCT) program and availability of 
treatment of human immunodeficiency virus(HIV) infected children has reduced the number of 
children acquiring HIV infection. In 2013, 200 000 (170 000–230 000) children were newly infected 
with HIV. This is 43% lower than in 2009. Twenty four per cent of children living with HIV received 
HAART, based on 2014 Joint United Nations Program for HIV/AIDS (UNAIDS) report.1   In South 
Africa 158,539 children are on HAART, of which 33,5% (53110) live in KZN.2 In the absence of 
treatment, it is estimated that 10-20% of infants can progress rapidly to acquired immunodeficiency 
syndrome (AIDS) in the first year of life and 80% of infected infants will demise in first 2 years of 
life.3 
 
The South African National HAART program started in 2004, and the recommended first line 
paediatric antiretroviral regimen was stavudine, lamivudine with either lopinavir/ritonavir(LPV/r) for 
children under the age of three, or efavirenz for children over the age of three. In 2010, the South 
African National HAART guidelines replaced stavudine with ABC in the first line regimen due to 
concerns of stavudine toxicity, following World Health Organization (WHO) recommendations. The 
eligibility criteria also changed from based on the patients WHO clinical stage or CD4 count to a treat 
all strategy for children under five years of age in 2013.4 
The ultimate aim of HAART is to reach virological suppression, which is defined as a viral load 
below 50copies/ml. Virological suppression is dependent on a variety of factors such as adherence 
and acquisition of mutations resulting in drug resistance.5 
Stavudine has a comparatively higher genetic barrier to resistance than abacavir(ABC), therefore 
theoretically a stavudine based regimen should be able to tolerate sub optimal compliance better than 
an ABC based regimen.6Exposure to sub-optimal HAART drug levels results in the virus acquiring 
mutations conferring resistance to the drug. The common drug resistance mutations to ABC are 
M184V/I, K65R,L74V. The combination of M184V/I and L74V reduces abacavir susceptibility more 
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than fivefold, whereas the M184V mutation actually reduces the resistance to stavudine.6In 
comparison, common drug resistance mutations to stavudine are thymidine analogue mutations 
(TAM) namelyM41L, L210W,D67N,K70R  T215Yand K219Q/E.TAMs are involved in resistance to 
all nucleoside reverse transcriptase inhibitors(NRTIs), except lamivudine (3TC), but the degree of 
cross-resistance depends on the NRTI considered and the number of TAMs on the virus. 
 
As mentioned earlier, adherence to HAART is essential to prevent drug resistance. Therefore the 
formulations of the different antiretroviral drugs is an important factor to ensure compliance. ABC is 
available as a paediatric syrup and tablet format and can be stored at room temperature. However 
stavudine oral solution requires refrigeration. The storage of these drugs is an especially important 
factor to consider in the rural setting where most households don't have access to electricity.7 
 
Coupled with the ease of administering and storage of treatment, the side effect profile is also of 
particular concern when considering the ideal regimen for children. Adverse events associated with 
stavudine include mitochondrial toxicity, peripheral neuropathy, lipoatrophy, pancreatitis, lactic 
acidosis/severe hepatomegaly, hyperlipidaemia and insulin resistance.Lipodystrophy syndrome refers 
to peripheral lipo-atrophy, central lipohypertrophy and dyslipidaemia associated with insulin 
resistance resulting in permanent disfigurement. 
In a recent review article , Innes et al described that lipodystrophy syndrome in HIV infected children 
on HAART was common in patients on didanosine, stavudine or zidovudine. The authors concluded 
that paediatric dosing of stavudine need to be reduced urgently to minimize the risk of lipodystrophy.8 
Abacavir is a NRTI with fewer side effects than stavudine. Its only potential dangerous side effect is a 
hypersensitivity reaction that is more common in the Caucasian population than African population 
due to the infrequency of the HLA B5701 haplotype in the African population.  A study by Walter 
Hughes et al concluded that abacavir is safe and well tolerated in children and the single abacavir 




Abacavir seems to be an ideal NRTI considering its formulation and low side effect profile. However 
there are conflicting results from the literature regarding the efficacy of an abacavir based regimen in 
producing virological suppression. 
 
The results from the Paediatric European Network for the Treatment of AIDS study (PENTA-
5)showed that an abacavir-containing NRTI regimen is more effective than zidovudine/lamivudine 
regimen and recommended that an abacavir containing NRTI will provide a good NRTI backbone for 
use with protease inhibitors and non-nucleoside reverse transcriptase inhibitors.10 
Similarly ,results from a randomised controlled trial of 480 African children that compared 
zidovudine, ABC and stavudine concluded that most HAART-naive children achieved viral load less 
than 400 copies per ml by 48 weeks, with no differences between randomised groups (p=0·58).11 
In contrast to the two clinical trials, Technau and Lazarus et al conducted a retrospective analysis of 
the virological outcomes among children receiving different starting regimens and concluded that 
children on an abacavir based regimen had a lower probability of virological suppression at six 
months and 12 months than those on a stavudine based regimen.12 
 
Similarly a South African Multi-Cohort Analysis was then conducted by Technau and Schomaker et 
al evaluating the virological response in children treated with abacavir compared with stavudine-
based antiretroviral treatment. The study concluded that there was reduced virological suppression at 
six months and 12 months in those children who were commenced on ABC based regimen compared 
to a stavudine based regimen.13 
There is currently no data available regarding the virological performance in children on an ABC 
based regimen in KwaZulu Natal. 
This study is a retrospective chart review to compare the virological responses of children 




The primary objectives were to describe the demographic characteristics (age, sex, WHO stage), 
baseline characteristics (CD4+ count, viral load, diagnosis of tuberculosis (TB), HAART regimen) and 
the virological responses at 12 months in children in the Abacavir cohort and to compare these to 












































This was a retrospective chart review of the routine patient clinic files. 
 
Study setting 
King Edward VIII hospital ARV clinic serves a large paediatric population in KwaZulu Natal. In 
2012, 220 children under the age of 12 yrs were diagnosed and initiated on HAART. 
 
Antiretroviral Treatment  
Patients were managed in compliance with the appropriate South African National HAART 
guidelines (2004-2013).  
In 2004 the first line regimen for children 6 months to 3 yrs was stavudine, lamivudine, 
lopinovir/ritonavir and for children older than 3 years the treatment was stavudine, lamivudine and  
efavirenz.  
The 2010 guideline changed the first line regimen for infants and children under the age of three to 
abacavir, lamivudine (3TC) and lopinavir/ritonavir and children older than three or more than 
10kg,abacavir, lamivudine and efavirenz(EFV). 
The initiation criteria for starting HAART in 2004 was ,2 or more hospital admissions for HIV related 
conditions in one year, or if the patient was classified as WHO stage 2 or 3, or if the patient was 
younger than eighteen months and CD4+ less than  20% , and if patient is older than eighteen months 
and  CD4+   is less than 15%. The patient also had to meet specific psychosocial criteria. 
The eligibility criteria for initiation of HAART in 2010 were (1) all children less than 1 year of age, 
(2)symptomatic infection (WHO stage 3 or 4) or CD4 <25% or <750cells/mm3 if age 1-5 years, and 
(3) symptomatic infection (WHO stage 3 or 4) or CD4 <350 cells/mm3 if age >5years. changed to all 
children under the age of five were eligible for HAART and children five to fifteen years of age 
qualified for HAART if they were WHO stage three or four or CD4+ <350cells/ul. 
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The 2010 guidelines required CD4+ counts and viral loads to be done at initiation of treatment. CD4+ 
counts were then monitored at 6 months, then at  12 months into HAART and then every 12 months. 
Viral loads were monitored at six months and then at 12 months, and then every 12 months.4  
Study participants 
All children under the age of 12 years ,who were commenced on an ABC based HAART regimen 
from 01 January 2012 to 31 December 2012 were included in the study and assigned to the ABC 
cohort group. 
The children had to be on an ABC based HAART regimen for at least 6 months. 
The exclusion criteria was children who were commenced on ABC based regimen for less than 6 
months and children commenced on a Stavudine based regimen. 
Our data was compared to data that was previously collected on all children that were commenced on 
a Stavudine based regimen at King Edward Hospital VIII between 2004 and 2009.15   This data 
obtained from 2004 to 2009 were assigned to the stavudine cohort group. 
Virological failure was defined as viral load less than 50copies/ml. 
Data collection and analysis 
In the abacavir cohort , the patient's demographics, clinical data, HAART regimen and laboratory 
results were obtained from file records and captured on a data capture sheet. Data was extracted on 
the 05 March 2015 from all children under the age of twelve years initiated on an ABC/3TC first-line 
regimen in combination with either EFV or LPV/r . 
In the stavudine based cohort , the patient's demographics, clinical data, HAART regimen and 
laboratory results were obtained from file records and captured in a standardized questionnaire and 
entered into an access data base. This data was transferred onto a new Microsoft excel spreadsheet 
and analysed using Intercooled Stata version 13. 
The data from the abacavir cohort group was then compared to the data from the  stavudine cohort.  
The data from the abacavir cohort was captured in Microsoft Excel and analysed using Intercooled 
Stata version 13. Descriptive statistics such as frequencies and percentages were used to summarise 
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results. Fisher’s exact test was used to test for association between virological suppression and other 
categorical variables. Logistic regression was used to test the effect of factors such as, age, sex, TB 
and WHO staging on viral suppression. To compare the median CD4 percentages at initiation between 
efavirenz and kaletra in the abacavir cohort, a two - sample Wilcoxon Rank Sum (Mann- Whitney) 
will be used. A p-value less than 0.05 was considered to be statistically significant. 
Viral load and CD4+  testing 
The laboratory tests are conducted by the central laboratory by the National Health Laboratory 
service. HIV diagnosis is based on two positive HIV antibody tests or one single positive HIV PCR in 
children > 18months or a single positive HIV PCR with a confirmatory viral detection assay in 
children <18months.Viral loads are measured with NucliSENSEasyQ HIV-1 version 1.2 from April 
2004–Nov 2009 and then NucliSENSEasyQ HIV-1 version 2.0 till Sept 2010, thereafter COBAS 
AmpliPrep/COBAS Taqman HIV-1 test. 
Ethics Approval 
Permission for the collection and analysis of routine clinic data has been obtained from the 












In the abacavir cohort there were 97 children who initiated highly active antiretroviral treatment at 
King Edward Hospital VIII from 01 January 2012 to 31 December 2012,of which  96% (94) were 
included in the study.The 3 files not included was due to missing files. Of the 94 children, 62, 8%(59) 
were initiated on ABC/3TC/EFV and 37.2%(35) were initiated on ABC/3TC/KAL. 
In the stavudine cohort  305 files were reviewed of which 65%(198) were included in the study. Of 
the patient files not included, 47,7%(51/107) were due to missing data and 52,3% (56/107) were due 
to missing files. As the stavudine data were collected for a previous retrospective chart review, I 
cannot provide an explanation as to why there were missing data and missing files. 
There was also a low rate ,52%(51/107) of viral load testing done among the stavudine group. It is 
unclear as to why there was such a low rate as the 2004 guidelines clearly state that viral load testing 
should be done at baseline and every 6 months.  Of the 198 children, 88.4%(175) were initiated on 
D4T/3TC/EFV and 11.6% (23) were initiated on D4T/3TC/KAL. The demographic characteristics of 
children in the abacavir cohort and stavudine cohort initiated on HAART are tabulated in table 1.  
In the abacavir cohort there were no difference in gender distribution and the median age of initiation 
was six years. Approximately forty eight percent of children were on TB treatment prior to initiation 
of HAART. The median CD4+ was 18% at time of initiation and the pre–treatment median viral load 
was 18915 copies/ml.  
Children on the kaletra based regimen had higher viral load copies as compared to children on 
efavirenz (p=<0.001). There was no statistical significant difference between CD4 at initiation of 
treatment (p=0.745) or WHO staging prior to treatment (p=0.091) between kaletra and efavirenz 
p=0.75). The median CD4 at initiation of Efavirenz was 18,2% and the median CD4 of kaletra was 
17,5%.Majority of the patients were classified as WHO stage 3 or 4. 
In the stavudine cohort there were predominantly more males 55.6% that were initiated on HAART  
as compared to 44.4% females. The mean age of initiation was 6.5 years. The WHO staging and TB 
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status were not obtained from the stavudine cohort as this data was not available from the stavudine 
data sheet that was collected previously. 
The virological suppression rates in the abacavir cohort at the 12 month follow up, were 83.3% of 
children commenced on ABC/3TC/EFV reached virological suppression and 76.5% of children 
commenced on ABC/3TC/KAL reached virological suppression. There was no statistical difference 
regarding virological suppression between Kaletra and Efavirenz group (p=0.43). These results are 
presented in table 3. 
In the stavudine based cohort , 85.2% of children commenced on the D4T based regimen reached 
virological suppression at the  12 month follow up. Approximately 14.8% did not reach virological 
suppression at 12 months. There is no statistical difference regarding virological suppression between 
KAL and EFV group (p=0.78). The results are presented in table 3. 
Logistic regression analysis was performed and CD4+, Age, TB, Sex, WHO staging were not 
associated with virological failures. See Table 2. 
There is no statistical significant difference ,when comparing the stavudine cohort to the abacavir 














Table 1:Demographic  Characteristics:  
 Total Number ABC regimen  Total Number D4T regimen 
Age in years 
at initiation  
Median 
86 6yrs (2-11yrs) 89 6.5yrs (4-8,8) 





CD4 % (at 
initiation) 
Median 





75 18915 copies/ml   







D4T/3TC/KAL:   
12% (23) 
TB (current 
TB at time of 
Diagnosis) 
89 48.3%    
WHO Stage 1 94 8.5%   
WHO Stage 2 9.6%   
WHO Stage 3 49.0%   






Table 2 Logistic Regression analysis to determine if the variable , CD4+, Age, TB, Sex, 
WHO staging were associated with virological failures 
  ABC D4T 





WHO staging 0.6 0.3 - 1.3   
TB 1.1 0.4 - 3.3   
Age in years 1.1 0.9 - 1.2 1.1 0.8 - 1.5 
Sex 1.5 0.5 – 4.6 0.8 0.3 - 2.3 
 
 
Table 3 The proportion of virologically suppressed children in both the ABC- and D4T 
regimen groups after 12 months of HAART 
  





ABC % Virologically 
Suppressed 
83.3.3% 76.5% 80.7% 
Number of Patients 45 26 71 
Not Virologically 
Suppressed 
ABC % Virologically 
Not Suppressed 
16.7% 23.5% 19.3% 





D4T % Virologically 
Suppressed 
84.8% 87.5% 85.2% 
Number of Patients 95 14 109 
Not Suppressed 
D4T % Virologically 
Not Suppressed 
15.2% 12.5% 14.8% 
Number of Patients 17 2 19 
 







ABC 80.7%(71) 19.3% (17) 88 
D4T 85.2%   (109) 14.8%     (19) 128 







The primary objective of this study was to compare the virological responses between an abacavir 
cohort and a stavudine based cohort. The importance of this study was to identify if lower virological 
effectiveness were seen in an abacavir cohort in our setting, as two other studies reported poorer 
virological responses in an abacavir containing regimen. 
 
In our study we found no difference in virological suppression rates between the abacavir cohort and 
stavudine cohort. (p value 0.38). Our study also provided evidence that there was good virological 
suppression (81.91% ) in both the EFV/KAL group. 
These results are in keeping with the Penta- 5 trial and Musiime trial, as these two randomised control 
trials showed no difference in virological suppression rates between an abacavir based regimen versus 
other NRTI regimens.10,11 
This is in contrast to the Gauteng studies where their findings showed a poorer performance of ABC-
containing regimen as compared to the stavudine based regimen. In the kaletra group , 76.5% on ABC 
versus 87.5% on D4T reached virological suppression, and similarly in the EFV group, 83.3% on 
ABC versus 84.8% on D4T  reached virological suppression.13 
Similarly in the retrospective analysis done by Technau et al they found differences in virological 
suppression rates with LPV/r- versus EFV-based regimens. In their study a stronger association was 
seen in the LPV/r-based regimens, where children on ABC had an almost 2-fold increased risk of 
failure to suppress (41% versus21%, log-rank p<0.0001) by 12 months. Children receiving EFV had 
an almost 2-foldhigher risk of rebound by 12 months after first suppression (35% versus 18%, log-
rankp=0.0001) if they were on ABC compared to d4T.14 
Our study provides reassuring data that children in our setting have a good probability of virological 
suppression on an abacavir regimen. 
We also aimed to describe the demographic and baseline characteristics of children on HAART in the 
abacavir cohort as the baseline data for the stavudine cohort was not available .  In the abacavir 
cohort, children on the kaletra based regimen had higher viral load copies as compared to children on 
efavirenz (p=<0.001). There was no statistical significant difference between CD4 at initiation of 
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treatment (p=0.745) or WHO staging prior to treatment (p=0.091) between kaletra and efavirenz. The 
higher viral load at initiation of treatment in children on a kaletra based regimen can be explained by 
the fact that children on kaletra are younger compared to children on efavirenz. A possible 
explanation for the high viral load could be that the level of viral replication is higher in infants and 
infants have a higher concentration of circulating CD4 T lymphocytes, which are the major target 
cells for HIV-1 replication. Another possibility for the high viral load can be secondary to a less 
robust early immune response to infection in infants. This is in keeping with a study done by 
Richardson et al that found that the average peak plasma HIV-1 viral loads are 1 log10 higher in 
infants than in adults.16 
 
The limitation of this study is that it’s a descriptive retrospective chart review with a small sample 
size and findings are from a single centre. Another limitation to the study was missing data and 
several patients were lost to follow up especially in the stavudine cohort. An important limitation to 
this study was the limited number of variables used to explore determinants of virological suppression 
e.g no information was obtained on adherence and therefore the inability to undertake a 
comprehensive evaluation of the determinants of virological suppression. An important concerning 
finding, was also the low rate of VL testing in all treatment groups at the six months and twelve 
months follow up. 
Conclusion 
This study is a retrospective chart review that compared virological responses between an abacavir 
cohort and a stavudine based cohort at King Edward Hospital Durban. This study demonstrates that 
children treated with an abacavir based regimen have a good probability of virological suppression, 
and there was no statistical difference between patients initiating an abacavir-based regimen versus a 
stavudine based regimen. These findings are in keeping with data from several clinical trials and 
support the WHO recommendation of an abacavir-based regimen for infants and children initiating 





1. World Health Organization, UNAIDS, UNICEF.2014 Progress Report on the global plan 
towards the elimination of new HIV infections among children by 2015 and keeping their 
mothers alive. Geneva: World Health Organization;2014. 
2. District Health Information system database. National department of Health. http://hisp.org/. 
March 2015. Based on DHIS data element 'Child remain on ART total'. 
 
3. McIntyre JA,Gray GE,Jivkov B,Violari A. Preventing Mother- to- child transmission of HIV-
1 in South Africa. The South African Journal of HIV medicine.2001;4:15-26 
4. National Department of Health. Guidelines for the Management of HIV in Children -
3rdEdition 2013. 2013. Pretoria: National Department of Health; 2013. rev. ed 
5. Calmy A,Ford N, Hirschel B Reynolds S,Leynen L,Goemaere E et al. HIV Viral Load 
Monitoring in Resource-Limited Regions: Optional or Necessary?.Clinical Infectious 
Diseases. 2007; 44:128–34 
 
6. Johnson VA,Calvez V, Gunthard HF,Wensing AM,F Huldrych, et al. 2014 update of the drug 
resistance mutations in HIV-1.Top Antivir Med.2014;22(3):642-650. 
7. formulations 
8. Innes S, Levin L, Cotton M. Lipodystrophy syndrome in HIV-infected children on HAART. 
South Afr J HIV Med.2009 December;10(4):76-80. 
9. Hughes W, McDowell JA, Shenep J,Flynn P,Kline MW,Yogev R et al. Safety and single dose 
pharmacokinetics of Abacavir in Human Immunodeficiency virus Type 1-infected Children. 
Antimicrob agents Chemother.1999 March;43(3):609-615. 
10. Penta 5 trial. Comparison of dual nucleoside-analogue reverse- transcriptase inhibitor 
regimens with and without nelfinavir in children with HIV-1 who have not previously been 
treated: PENTA 5 randomised trial.Lancet 2002;359:733-40 
49 
 
11. Musiime V, Mulenga V, Kekitiinwa A, Cook A, Abongomera G, Thomason MJ, et al. 
CHAPAS 3: A randomised trial comparing stavudine vs. zidovudine vs. abacavir as NRTI 
backbone in NNRTI-based first-line ART in 478 HIV-infected children in Uganda and 
Zambia. Rev Antiviral Ther Infect Dis. 2014;6:22. 
12. Brennan AT, Maskew M, Long L, Sanne I, Fox MP, Conradie F. 24-month treatment 
outcomes amongst HIV-positive children and adolescent patients prescribed stavudine vs. 
abacavir. 20th International AIDS Conference, Melbourne, Australia 20 – 25 July 
2014.http://pag.aids2014.org/EPosterHandler.axd?aid=2246. Accessed 15 Aug 2014. 
13. Technau K, Lazarus E, Kuhn L,Abrams EJ,Sorour G et al. Poor Early Virologic Performance 
and Durability of Abacavir based First-line Regimens for HIV-infected Children. Pediatr 
Infect Dis J. 2013 August; 32(8): 851–855. 
14. Technau K, Schomaker M, Kuhn L,Moultrie H,Coovadia A et al. Virologic Response in 
Children Treated with Abacavir Compared with Stavudine-Based Antiretroviral Treatment – 
A South African Multi-Cohort Analysis. Pediatr Infect Dis J. 2014 June; 33(6): 617–622 
15. Naidoo K, Archary M, Bobat RA. A 60 month retrospective review of outcomes of HIV 
positive children on anti-retroviral treatment at a public sector hospital in South Africa. 
Reviews in anti-retroviral therapy infectious diseases 8. 2011 
16. Richardson BA, Mboringacha , Overbaugh J. Comparison of human immunodeficiency virus 
Type 1 viral loads in Kenyan women, men, and infants during primary and early infection. 











Appendix 1: The final Study Protocol 
Research Proposal 
 
Research topic: Comparison of virological responses of children commenced on an Abacavir versus a 
Stavudine based Antiretroviral regimen at King Edward VIII hospital, Durban. 
 
Nature of study: 
Quantative Study 
Type of study 
Retrospective chart review 
Objective 
Primary Objective: 
1. To describe the demograpic characteristics (age, sex, WHO stage) of children commenced on 
an Abacavir(ABC) based HAART regimen at King Edward VIII Hospital from January 2012 
to December 2012. 
2. To describe the baseline characteristics (CD4 count, Viral load, Diagnosis of TB, ART 
regimen) of children commenced on an Abacavir(ABC) based HAART regimen at King 
Edward VIII Hospital from January 2012 till December 2012. 
3. To describe the virological responses (VL < 1000 = virological response/ VL > 1000 = 
virological failure) at 12 months in children commenced on an Abacavir(ABC) based 
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HAART regimen at King Edward VIII Hospital from January 2012 till December 2012 and to 
compare these to children in the stavudine cohort 
 
 
Summary of the proposed research  
 
Improvement in the PMTCT program and availability of treatment of HIV infected 
Children have reduced the number of children acquiring HIV infection. Following the World 
Health Organization recommendations, the South African Antiretroviral treatment guideline in 
2010,replaced stavudine with abacavir in the first line HAART regimen, due to the concerns of 
stavudine toxicity. 
The proposed research aim to evaluate the virological performance in all children started on the ABC 
based HAART regimen at King Edward Hospital VIII Hospital from January 2012 till December 
2012.This is a retrospective chart review that will review selected patient records from the hospital 
database.  
Viral load will be used to assess the virological performance. Ethical permission will be sought from 















Improvement in the PMTCT program and availability of treatment of HIV infected children has 
reduced the number of children acquiring HIV infection. In 2011, 330 000 children acquired HIV 
infection. This represents a 43% decline since 2003.More than 90% of these children acquiring HIV 
infection live in sub-Saharan Africa.1 
The route of infection in children is mainly through vertical transmission( 95%). Of which 
approximately 10% is acquired transplacentally,60% in the peripartum period and 30% through 
breastfeeding (30%). Children can also acquire the virus through sexual abuse and blood product 
transfusion. In resource poor communities in the absence of treatment, it is estimated that 10-20% of 
infants can progress rapidly to AIDS in the first year of life and 80% of infected infants will demise in 
first 2 years of life.2 
The plasma HIV RNA (viral load) provides an accurate means of quantifying the response to 
treatment. Effective HAART regimens taken with high levels of adherence result in a decrease of 
viral load by at least 1 log per month and suppression to a viral load below 50copies/ml will generally 
be achieved in 16-24 weeks. The use of CD4+ cell counts and viral load provide a better estimate of 
the risk of disease progression.3 
The initial treatment included in the first line regimen was stavudine, lamivudine with either 
Ritonavir- lopinavir for children under the age of 3,or efavirenz for children over the age of 3. 
In 2010, the South African Antiretroviral treatment guidelines replaced stavudine with abacavir in the 
first line regimen due to the concerns of stavudine toxicity, following the World Health Organization 
recommendations. In 2013 the eligibility criteria also changed in that all children under the age of 5 
must start HAART irrespective of CD4 count.4 
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The adverse events of stavudine include mitochondrial toxicity, peripheral neuropathy, lipoatrophy, 
pancreatitis, lactic acidosis/severe hepatomegaly, hyperlipidaemia and insulin resistance. 
A study done by Steve Innes et al, published in August 2010 looked at lipodystrophy syndrome in 
HIV infected children on HAART which is common in those taking didanosine, stavudine or 
zidovudine. Lipodystrophy syndrome refers to peripheral lipo-atrophy, central lipohypertrophy and 
dyslipidaemia associated with insulin resistance. They concluded that paediatric dosing of stavudine 
need to be reduced urgently to minimize the risk of lipodystrophy.5 
Linda Barlow-Mosha et al published an article in the Journal of the International AIDS society in 
April 2013 on metabolic complications and treatment of perinatally HIV- infected children and 
adolescents and concluded that nucleoside reverse transcriptase inhibitors, particularly Stavudine, 
zidovudine and didanosine are linked to development of lipodystrophy and lactic acidosis.6 
 
Abacavir is a nucleoside reverse transcriptase inhibitor with fewer side effects than stavudine. Its only 
potential dangerous side effect is a hypersensitivity reaction that is more common in the Caucasian 
population than African population.  A study done by Walter Hughes et al in 1998 on safety and 
single dose pharmacokinetics of abacavir in human immunodeficiency virus type 1- infected children 
concluded that abacavir is safe and well tolerated in children and the single abacavir related adverse 
event was the hypersensitivity reaction.7 
Another study by Chaponda et al published in August 2010 looked at hypersensitivity reactions to 
HIV therapy and concluded that the Abacavir hypersensitivity reaction occurs in 2.3-9% of adults and 
children with some differences in ethnicity.8 
 A study done at the Empilweni clinic at Rahima Moosa Mother and Child hospital in Johannesburg 
published in 2013, compared the virological performance of the abacavir based first line regimen with 
the stavudine based regimen. The study concluded that the Abacavir based regimen showed a 
significantly poorer virological performance as compared with the Stavudine based regimen.9 
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The Paediatric European Network for the treatment of AIDS (PENTA-5) trial from 1998-1999 
demonstrated that the combination of lamivudine/abacavir has virological superiority over 
AZT/Lamivudine and AZT/ABC. This trial also concluded that Abacavir has the least effect on 
mitochondrial DNA and its only associated serious side effect is hypersensitivity reaction that is more 
prevalent in Caucasians than the African population.10 
Another study that was done from April 2004 to March 2008, looked at Antiretroviral therapy 
responses among children attending a large public clinic in Soweto. This study concluded that 
children that were started on the lamivudine/stavudine/LPV/r or lamivudine/stavudine/ EFV regimen 
achieved an 84% and 96% virological suppression at 12months and 24 months respectively. 
Virological suppression was defined as achieving a viral load less than 400 copies/ml. Children 
younger than 3yrs and with higher viral loads suppressed their viral loads more slowly than older 
children. The mean CD4 percentage doubled within 12months of initiation, rising from 12.7% to 
25.1%. Their findings demonstrated excellent virological and immunological suppression rates.11 
The PenPact- 1 trial from 2002-2005 conducted in children from Europe and South America, 
compared first line antiretroviral therapy with a protease inhibitor versus a non- nucleoside reverse 
transcriptase inhibitor and demonstrated no significant differences in virological, immunological and 
clinical outcomes.12 



















This was a retrospective chart review of the routine patient clinic files. 
 
Study setting 
King Edward VIII hospital ARV clinic serves a large paediatric population in KwaZulu Natal. In 
2012, 220 children under the age of 12 yrs were diagnosed and initiated on HAART. 
 
Antiretroviral Treatment  
Patients were managed in compliance with the appropriate South African National HAART 
guidelines (2004-2013).  
In 2004 the first line regimen for children 6 months to 3 yrs was stavudine, lamivudine, 
lopinovir/ritonavir and for children older than 3 years the treatment was stavudine, lamivudine and  
efavirenz.  
The 2010 guideline changed the first line regimen for infants and children under the age of three to 
abacavir, lamivudine (3TC) and lopinavir/ritonavir and children older than three or more than 
10kg,abacavir, lamivudine and efavirenz(EFV). 
The initiation criteria for starting HAART in 2004 was ,2 or more hospital admissions for HIV related 
conditions in one year, or if the patient was classified as WHO stage 2 or 3, or if the patient was 
younger than eighteen months and CD4+ less than  20% , and if patient is older than eighteen months 
and  CD4+   is less than 15%. The patient also had to meet specific psychosocial criteria. 
The eligibility criteria for initiation of HAART in 2010 were (1) all children less than 1 year of age, 
(2)symptomatic infection (WHO stage 3 or 4) or CD4 <25% or <750cells/mm3 if age 1-5 years, and 
(3) symptomatic infection (WHO stage 3 or 4) or CD4 <350 cells/mm3 if age >5years. changed to all 
children under the age of five were eligible for HAART and children five to fifteen years of age 
qualified for HAART if they were WHO stage three or four or CD4+ <350cells/ul. 
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The 2010 guidelines required CD4+ counts and viral loads to be done at initiation of treatment. CD4+ 
counts were then monitored at 6 months, then at  12 months into HAART and then every 12 months. 
Viral loads were monitored at six months and then at 12 months, and then every 12 months.4  
Study participants 
All children under the age of 12 years ,who were commenced on an ABC based HAART regimen 
from 01 January 2012 to 31 December 2012 were included in the study and assigned to the ABC 
cohort group. 
The children had to be on an ABC based HAART regimen for at least 6 months. 
The exclusion criteria was children who were commenced on ABC based regimen for less than 6 
months and children commenced on a Stavudine based regimen. 
Our data was compared to data that was previously collected on all children that were commenced on 
a Stavudine based regimen at King Edward Hospital VIII between 2004 and 2009.15   This data 
obtained from 2004 to 2009 were assigned to the stavudine cohort group. 
Virological failure was defined as viral load less than 50copies/ml. 
Data collection and analysis 
In the abacavir cohort , the patient's demographics, clinical data, HAART regimen and laboratory 
results were obtained from file records and captured on a data capture sheet. Data was extracted on 
the 05 March 2015 from all children under the age of twelve years initiated on an ABC/3TC first-line 
regimen in combination with either EFV or LPV/r . 
In the stavudine based cohort , the patient's demographics, clinical data, HAART regimen and 
laboratory results were obtained from file records and captured in a standardized questionnaire and 
entered into an access data base. This data was transferred onto a new Microsoft excel spreadsheet 
and analysed using Intercooled Stata version 13. 
The data from the abacavir cohort group was then compared to the data from the  stavudine cohort.  
The data from the abacavir cohort was captured in Microsoft Excel and analysed using Intercooled 
Stata version 13. Descriptive statistics such as frequencies and percentages were used to summarise 
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results. Fisher’s exact test was used to test for association between virological suppression and other 
categorical variables. Logistic regression was used to test the effect of factors such as, age, sex, TB 
and WHO staging on viral suppression. To compare the median CD4 percentages at initiation between 
efavirenz and kaletra in the abacavir cohort, a two - sample Wilcoxon Rank Sum (Mann- Whitney) 
will be used. A p-value less than 0.05 was considered to be statistically significant. 
Viral load and CD4+  testing 
The laboratory tests are conducted by the central laboratory by the National Health Laboratory 
service. HIV diagnosis is based on two positive HIV antibody tests or one single positive HIV PCR in 
children > 18months or a single positive HIV PCR with a confirmatory viral detection assay in 
children <18months.Viral loads are measured with NucliSENSEasyQ HIV-1 version 1.2 from April 
2004–Nov 2009 and then NucliSENSEasyQ HIV-1 version 2.0 till Sept 2010, thereafter COBAS 
AmpliPrep/COBAS Taqman HIV-1 test. 
Ethics Approval 
Permission for the collection and analysis of routine clinic data has been obtained from the 
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Appendix 3: The Guidelines for Authorship for the Journal selected for submission of 
the manuscript 
 
Instructions to authors: SAHIVJ: www.sajhivmed.org.za 
Structure and style of your original research article 
The page provides an overview of the structure and style of your original research article to 
be submitted to the Southern African Journal of HIV Medicine. The original article provides an 
overview of innovative research in a particular field within or related to the focus and scope 
of the journal presented according to a clear and well-structured format (between 3500 and 
5500 words with a maximum of 60 references). 
Please use British English, that is, according to the Oxford English Dictionary. Avoid 
Americanisms (e.g. use ‘s’ and not ‘z’). Consult the Oxford English Dictionary when in doubt 
and remember to set your version of Microsoft Word to UK English. 
 Language: Manuscripts must be written in British English. 
 Font: 
o Font type: Palatino  
o Symbols font type: Times New Roman  
o General font size: 12pt  
 Line spacing: 1.5 
 Headings: Ensure that formatting for headings is consistent in the manuscript. 
o First headings: normal case, bold and 14pt 
o Second headings: normal case, underlined and 14pt 
o Third headings: normal case, bold and 12pt 
o Fourth headings: normal case, bold, running-in text and separated by a colon. 
Our publication system supports a limited range of formats for text and graphics. Text files 
can be submitted in the following formats only: 
 Microsoft Word (.doc): We cannot accept Word 2007 DOCX files. If you have created your 
manuscript using Word 2007, you must save the document as a Word 2003 file before 
submission. 
 Rich Text Format (RTF) documents uploaded during Step 2 of the submission process. Users 
of other word processing packages should save or convert their files to RTF before uploading. 
Many free tools are available that will make  this process easier. 
 For full details on how to ensure your manuscript adheres to the house style, click here. 
The structure and style of your original article 
Page 1 
The format of the compulsory cover letter forms part of your submission and is on the first 
page of your manuscript and should always be presented in English. You should provide all of 
the following elements: 
 Article title: Provide a short title of 50 characters or less. 
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 Significance of work: Briefly state the significance of the work being reported on. 
 Full author details: Provide title(s), full name(s), position(s), affiliation(s) and contact 
details (postal address, email, telephone and cellular number) of each author.  
 Corresponding author: Identify to whom all correspondence should be addressed to. 
 Authors’ contributions: Briefly summarise the nature of the contribution made by each of 
the authors listed. 
 Summary: Lastly, a list containing the number of words, pages, tables, figures and/or other 
supplementary material should accompany the submission. 
Page 2 and onwards 
Title: The article’s full title should contain a maximum of 95 characters (including spaces). 
Abstract: The abstract, written in English, should be no longer than 250 words and must be 
written in the past tense. The abstract should give a succinct account of the objectives, 
methods, results and significance of the matter. The structured abstract for an original 
research article should consist of five paragraphs that are labelled. These labelled paragraphs 
should deal with the background, objectives, method, results and conclusion.  
 Background: Why do we care about the problem?  State the context and purpose of the 
study. (What practical, scientific or theoretical gap is your research filling?) 
 Objectives: What problem are you trying to solve? What is the scope of your work (e.g. is it 
a generalised approach or for a specific situation)? Be careful not to use too much jargon. 
 Method: How did you go about solving or making progress on the problem? State how the 
study was performed and which statistical tests were used. (What did you actually do to get 
the results?) Clearly express the basic design of the study; name or briefly describe the basic 
methodology used without going into excessive detail. Be sure to indicate the key techniques 
used. 
 Results: What is the answer? Present the main findings (that is, as a result of completing the 
procedure or study, state what  you have learnt, invented or created). Identify trends, 
relative change or differences on answers to questions. 
 Conclusion: What are the implications of your answer? Briefly summarise any potential 
implications. (What are the larger implications of your findings, especially for the problem or 
gap identified in your motivation?) 
Do not cite references in the abstract and do not use abbreviations excessively in the 
abstract. 
The following headings serve as a guide for presenting your research in a well-structure 
format. As an author you should include all first level headings but subsequent headings 
(second and third level headings) can be changed. 
Introduction (first-level heading)  
The introduction contains two subsections, namely the background section and the literature 
review. The introduction section should be written from the standpoint of readers that is 
without specialist knowledge in that area and must clearly state the introduction to the 
research and its aims in the context of previous work bearing directly on the subject. The 
introduction section to the article normally contains the following five elements: 
 Key focus (third-level heading): A thought-provoking introductory statement on the broad 
theme or topic of the research.   
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 Background (third-level heading: Providing the background or the context to the study 
(explaining the role of other relevant key variables in this study).  
 Trends (third-level heading): Cite the most important published studies previously 
conducted on this topic or that has any relevance to this study (provide a high-level synopsis 
of the research literature on this topic).   
 Objectives (third-level heading): Indicate the most important controversies, gaps and 
inconsistencies in the literature that will be addressed by this study. In view of the above 
trends, state the core research problem and specific research objectives that will be 
addressed in this study and provide the reader with an outline of what to expect in the rest of 
the article.   
 Contribution to field (third-level heading): Explanation of the study’s academic 
(theoretical and methodological) or practical merit and/or importance (provide the value-add 
and/or rationale for the study).  
Research design (first-level heading) 
 Research appraoch (second-level heading) 
 Research method (second-level heading) 
o Materials (third-level heading): Describe the type of organism(s) or material(s) involved 
in the study.   
o Setting (third-level heading): Describe the site and setting where your field study was 
conducted.   
o Design (third-level heading): Describe your experimental design clearly, including a power 
calculation if appropriate. Note: Additional details can be placed in the online supplementary 
location.   
o Procedure (third-level heading): Describe the protocol for your study in sufficient detail 
(clear description of all interventions and comparisons) that other scientists could repeat your 
work to verify your findings.   
o Statistical analysing (third-level heading): Describe how the data were summarised and 
analysed, additional details can be placed in the online supplementary information. 
o Reliability (third-level heading): Reliability is the extent to which an experiment, test, or 
any measuring procedure yields the same result on repeated trials. Without the agreement of 
independent observers able to replicate research procedures, or the ability to use research 
tools and procedures that yield consistent measurements,  researchers would be unable to 
satisfactorily draw  conclusions, formulate theories, or make claims about the generalisability 
of their research.     
o Validity (third-level heading): Validity refers to the degree to which a study accurately 
reflects or assesses the specific concept that the researcher is attempting to measure. While 
reliability is concerned with the accuracy of the actual measuring instrument or procedure, 
validity is concerned with the study's success at measuring what the researchers set out to 
measure. Researchers should be concerned with both external and internal validity. External 
validity refers to the extent to which the results of a study are generalisable or transferable. 
Internal validity refers to (1) the rigor with which the study was conducted (e.g. the study's 
design, the care taken to conduct measurements, and decisions concerning what was and 
wasn't measured) and (2) the extent to which the designers of a study have taken into 
account alternative explanations for any causal relationships they explore. In studies that do 
not explore causal relationships, only the first of these definitions should be considered when 
assessing internal validity.   
o Ethical considerations (third-level heading):Articles based on the involvement of people 
must have been conducted in accordance with relevant national and international guidelines. 
Approval must have been obtained for all protocols from the author's institutional or other 
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relevant ethics committee and the institution name and permit numbers provided at 
submission.  
 Potential benefits and hazards (fourth-level heading): What risks to the subject are 
entailed in involvement in the research? Are there any potential physical, psychological or 
disclosure dangers that can be anticipated? What is the possible benefit or harm to the 
subject or society from their participation or from the project as a whole? What  procedures 
have been established for the care and protection of subjects (e.g. insurance, medical cover) 
and the control of any information gained from them or about them?   
 Recruitment procedures (fourth-level heading): Was there any sense in which subjects 
might be ‘obliged’ to participate – as in the case of students, prisoners, learners or patients – 
or were volunteers being recruited? If participation was compulsory, the potential 
consequences of non-compliance must be indicated to subjects; if voluntary, entitlement to 
withdraw consent must be indicated and when that entitlement lapses   
 Informed consent (fourth-level heading): Authors must include how informed consent 
was handled in the study.   
 Data protection (fourth-level heading: Authors must include in detail the way in which 
data protection was handled. 
Results (first-level heading)  
This section provides a synthesis of the obtained literature grouped or categorised according 
to some organising or analysis principle.   
Tables may be used and models may be drafted to indicate key components of the results of 
the study. 
 Organise the results based on the sequence of Tables and Figures you will include in the 
manuscript. 
 The body of the Results section is a text presentation of the key findings which includes 
references to each of the Tables and Figures. 
 Statistical test summaries (test name, p-value) are usually reported parenthetically in 
conjunction with the biological results they support. 
 Present the results of your experiment(s)/research data in a sequence that will logically 
support (or provide evidence against) the hypothesis, or answer the question, stated in the 
Introduction. 
All units should conform to the SI convention and should be abbreviated accordingly. Metric 
units and their international symbols are used throughout, as is the decimal point (not the 
decimal comma).   
Discussion (first-level heading)    
This section normally contains the following elements (it is strongly suggested that sub-
headings are used in this section): 
 Outline of the results (second-level heading): Restate the main objective of the study 
and reaffirm the importance of the study by restating its main contributions; Summarise the 
results in relation to each stated research objective or research hypothesis; link the findings 
back to the literature and to the results reported by other researchers; provide explanations 
for unexpected results.   
 Practical implications (second-level heading): Reaffirm the importance of the study by 
restating its main contributions and provide the implications for the practical implementation 
your research.   
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 Limitations of the study (second-level heading): Point out the possible limitations of the 
study and provide suggestions for future research. 
 Recommendations (second-level heading): Provide the recommendations emerging out 
of the current research. 
Conclusion (first-level heading)  
This should state clearly the main conclusions of the research and give a clear explanation of 
their importance and relevance, with a recommendation for future research (implications for 
practice). Provide a brief conclusion that restates the objectives, the research design, the 
results and their meaning. 
Acknowledgements (first-level heading)  
If, through your study, you received any significant help in conceiving, designing, or carrying 
out the work, or received materials from someone who did you a favour by supplying them, 
you must acknowledge their assistance and the service or material provided. Authors 
should always acknowledge outside reviewers of their drafts and any sources of 
funding that supported the research. 
 Competing interests (second-level heading): A competing interest exists when your 
interpretation of data or presentation of information may be influenced by your personal or 
financial relationship with other people or organisations that can potentially prevent you from 
executing and publishing unbiased research. Authors should disclose any financial competing 
interests but also any non-financial competing interests that may cause them embarrassment 
were they to become public after the publication of the manuscript. Where an author gives 
no competing interests, the listing will read ‘The authors declare that they have no 
financial or personal relationship(s) which may have inappropriately influenced 
them in writing this article.’    
 Authors' contributions (second-level heading)*: This section is necessary to give 
appropriate credit to each author, and to the authors' applicable institution. The individual 
contributions of authors should be specified with their affiliation at the time of the study and 
completion of the work. An ‘author’ is generally considered to be someone who has made 
substantive intellectual contributions to a published study.  Contributions made by each of 
the authors listed, along the lines of the following (please note the use of author initials): 
J.K. (University of Pretoria) was the project leader, L.M.N. (University of KwaZulu-Natal) and 
A.B. (University of Stellenbosch) were responsible for experimental and project design. 
L.M.N. performed most of the experiments. P.R. made conceptual contributions and S.T. 
(University of Cape Town), U.V. (University of Cape Town) and C.D. (University of Cape 
Town) performed some of the experiments. S.M. (Cape Peninsula University of Technology) 
and V.C. (Cape Peninsula University of Technology) prepared the samples and calculations 
were performed by C.S., J.K. (Cape Peninsula University of Technology) and U.V. wrote the 
manuscript. 
References (first-level heading) 
Begin the reference list on a separate page with no more than 60 references. Southern 
African Journal of HIV Medicine uses the Vancouver referencing style, details of which can 
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